Inari Medical, Inc. (NASDAQ:NARI) Director Sells $2,002,000.00 in Stock

Inari Medical, Inc. (NASDAQ:NARI) Director William Hoffman sold 40,000 shares of the company’s stock in a transaction dated Tuesday, October 29th. The stock was sold at an average price of $50.05, for a total transaction of $2,002,000.00. Following the completion of the transaction, the director now owns 561,233 shares of the company’s stock, valued at approximately $28,089,711.65. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

William Hoffman also recently made the following trade(s):

• On Wednesday, October 16th, William Hoffman sold 40,000 shares of Inari Medical stock. The stock was sold at an average price of $45.02, for a total transaction of $1,800,800.00.
• On Monday, September 16th, William Hoffman sold 40,000 shares of Inari Medical stock. The stock was sold at an average price of $45.83, for a total transaction of $1,833,200.00.

Inari Medical Price Performance

Inari Medical stock opened at $48.74 on Friday. The firm has a 50 day simple moving average of $43.66 and a 200-day simple moving average of $46.05. Inari Medical, Inc. has a 1-year low of $36.73 and a 1-year high of $67.13. The stock has a market cap of $2.85 billion, a price-to-earnings ratio of -36.10 and a beta of 0.96.

Analyst Ratings Changes

NARI has been the subject of several research analyst reports. Robert W. Baird upped their price target on shares of Inari Medical from $66.00 to $67.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 29th. Wells Fargo & Company reduced their price target on shares of Inari Medical from $84.00 to $65.00 and set an “overweight” rating for the company in a research report on Wednesday, July 31st. Truist Financial upped their price target on shares of Inari Medical from $46.00 to $50.00 and gave the stock a “hold” rating in a research report on Tuesday, October 29th. Stifel Nicolaus began coverage on shares of Inari Medical in a report on Tuesday, September 17th. They issued a “hold” rating and a $50.00 price objective for the company. Finally, Leerink Partnrs upgraded shares of Inari Medical to a “hold” rating in a report on Tuesday, September 3rd. Six equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, Inari Medical has an average rating of “Hold” and an average price target of $58.89.

Institutional Trading of Inari Medical

Several hedge funds have recently made changes to their positions in the company. Bessemer Group Inc. grew its stake in shares of Inari Medical by 16.4% in the 1st quarter. Bessemer Group Inc. now owns 2,439 shares of the company’s stock valued at $117,000 after buying an additional 344 shares during the period. Wealth Enhancement Advisory Services LLC boosted its position in shares of Inari Medical by 7.7% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 4,852 shares of the company’s stock worth $234,000 after purchasing an additional 348 shares during the period. Arizona State Retirement System boosted its position in shares of Inari Medical by 2.5% during the 2nd quarter. Arizona State Retirement System now owns 14,602 shares of the company’s stock worth $703,000 after purchasing an additional 358 shares during the period. Covestor Ltd boosted its position in shares of Inari Medical by 30.2% during the 1st quarter. Covestor Ltd now owns 1,619 shares of the company’s stock worth $78,000 after purchasing an additional 376 shares during the period. Finally, Nisa Investment Advisors LLC boosted its position in shares of Inari Medical by 83.5% during the 2nd quarter. Nisa Investment Advisors LLC now owns 956 shares of the company’s stock worth $46,000 after purchasing an additional 435 shares during the period. Hedge funds and other institutional investors own 90.98% of the company’s stock.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.